TCM
TTPH

Teza Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Teza Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-783
Closed -$144K – 438
2017
Q1 		$144K Buy
783
+65
+9% +$7.29K 0.04% 455
2016
Q4 		$58K Buy
+718
New +$56.8K 0.08% 219

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Teza Capital Management's TTPH Position: Q2 2017 in Review

Teza Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2017, closing a stake of 783 shares — an estimated $144K sold.

Teza Capital Management first reported a position in TTPH in Q4 2016 and held it in 2 quarters. The position peaked at $144K in Q1 2017. 90 funds tracked by Wall St. Rank hold TTPH as of Q2 2017.

  • Teza Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Teza Capital Management sold 783 Tetraphase Pharmaceuticals, Inc. shares in Q2 2017, an estimated $144K.
  • Teza Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
  • Teza Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $144K in Q1 2017.
  • 90 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2017.

Based on Teza Capital Management's 13F filing for Q2 2017.